16:36 EDT Plus Therapeutics (PSTV) files to sell 1.57B shares of common stock for holders
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements
- Plus Therapeutics’ Optimistic Earnings Call Highlights
- Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating
- Plus Therapeutics price target lowered to $5.50 from $8 at H.C. Wainwright
- Plus Therapeutics Reports 2024 Financial Results and Progress